Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in Florida
30 open options
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia
ITI-1284 · Placebo — 70 sites
- TRIALNANOT_YET_RECRUITING
Center for Research and Education on Aging and Technology Enhancement - CREATE V - Project 2
Project 2, Phase 2: Intelligent Adaptive System — 3 sites
- TRIALNARECRUITING
Neurologic Stem Cell Treatment Study
Intravenous and Intranasal BMSC — 3 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 159 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
Placebo (Study Part 1a) · ACI-24.060 at Dose A in Study Part 1a · ACI-24.060 at Dose B in Study Part 1a — 26 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
KarXT · Placebo — 129 sites
- TRIALNARECRUITING
Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease
Symani Surgical System — 3 sites
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 212 sites
- TRIALPHASE1 / PHASE2RECRUITING
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
ABBV-1758 · Placebo for ABBV-1758 · ABBV-1758 — 12 sites
- TRIALPHASE1 / PHASE2RECRUITING
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
18F-OP-801 — 3 sites
- TRIALPHASE3RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule · Xanomeline Enteric Capsule · Placebo — 145 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
KarXT · KarX-EC · KarXT + KarX-EC Arm Matching Placebo — 22 sites
- TRIALPHASE2RECRUITING
Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type
12 cm2 - 2 Active DMTS Patches · 6 cm2 - 1 Active and 1 Placebo DMTS Patches · Placebo - 2 Placebo DMTS Patches — 8 sites
- TRIALNARECRUITING
Effects of Transcranial Focused Ultrasound Stimulation (tFUS) on Neurological and Cognitive Outcomes in Parkinson's Disease
Gen0Bh Transcranial Focused Ultrasound System (Active) · Gen0Bh Transcranial Focused Ultrasound System (Sham) — 4 sites
- TRIALPHASE2RECRUITING
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
Mivelsiran · Placebo — 2 sites
- TRIALPHASE2 / PHASE3RECRUITING
ACP-204 in Adults With Alzheimer's Disease Psychosis
ACP-204 · Placebo — 148 sites
- TRIALPHASE2RECRUITING
Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
human Mesenchymal Stem Cells — 1 site
- TRIALNARECRUITING
Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP)
Palliative Care Training — 2 sites
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALPHASE3RECRUITING
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
Masupirdine 50 mg · Masupirdine 100 mg · Placebo — 44 sites
- TRIALNARECRUITING
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
Cognitive Training · Computerized Cognitive Stimulation — 6 sites
- TRIALPHASE4RECRUITING
Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease
18-F-Flortaucipir — 2 sites
- TRIALNARECRUITING
Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among Blacks
Standard of Care · Personalized OSA Treatment — 1 site
- TRIALPHASE2RECRUITING
Cognitive Training and Neuroplasticity in Mild Cognitive Impairment: COGIT-2 Trial
Cognitive Training — 4 sites
- TRIALPHASE1 / PHASE2RECRUITING
Low-Dose Radiotherapy for Alzheimer's Disease
Low Dose Radiation Therapy — 1 site
- TRIALPHASE1 / PHASE2RECRUITING
Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease
SNK01 · Placebo — 8 sites
- TRIALPHASE3RECRUITING
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
KarXT · Placebo — 154 sites
- TRIALPHASE2RECRUITING
Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease
LHP588 · LHP588 · Placebo Drug — 40 sites
- TRIALPHASE2RECRUITING
Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
BMS-986368 · Placebo — 75 sites
- TRIALNARECRUITING
Combating Alzheimer's Through Sleep and Exercise
DREEM 2 Headband · Exercise Routine — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.